TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases

Current Drug Targets

Volumn 13, Issue 9, 2012, Pages 1215-1221

  Bernardi, Stella ^a,b   Milani, Daniela ^a   Fabris, Bruno ^b   Secchiero, Paola ^a   Zauli, Giorgio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

Cardiovascular diseases; Diabetes; TRAIL

Indexed keywords

BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; INFLAMMATORY CELL; MEDICAL LITERATURE; NONHUMAN; PROGNOSIS; REVIEW; THERAPY EFFECT; VASCULAR SMOOTH MUSCLE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; PROGNOSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84864552394     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802002357     Document Type: Review

References (63)

1. Frieden TR, Berwick DM. The "Million Hearts" initiative-Preventing heart attacks and strokes. N Engl J Med 2011; e27: 1-4.
2. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16.
3. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-8.
4. Ren MY, Sui SJ, Zhang Y, et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol 2008; 63: 615-22.
5. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-4.
6. Semb AG, Ueland T, Aukrust P, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009; 29: 957-80.
7. Zauli G, Corallini F, Bossi F, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110: 536-43.
8. Secchiero P, Corallini F, Beltrami AP, et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010; 210: 274-7.
9. Mogelvang R, Pedersen SH, Flyvbjerg A, et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and highsensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012; 109: 515-20.
10. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.
11. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
12. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331-40.
13. Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 2008; 15: 42-8.
14. Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-61.
15. Sedger LM, Glaccum MB, Schuh JC, et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002; 32: 2246-54.
16. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2ligand. J Clin Invest 1999; 104: 155-62.
17. Ashkenazi A. Directing cancer cells to self-destruct with proapoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001-12.
18. Lincz LF, Yeh TX, Spencer A. TRAIL-induced eradication of primary Tumor cells from from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15: 1650-7.
19. Campioni D, Secchiero P, Corallini F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005; 166: 557-63.
20. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 2001; 15: 921-8.
21. Secchiero P, Zerbinati C, di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8: 395-403.
22. Kim K, Fisher MJ, Xu SQ, et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335-46.
23. Lancaster JM, Sayer R, Blanchette C, et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 2003; 9: 762-6.
24. Milani D, Zauli G, Rimondi E, et al. Tumour necrosis factorrelated apoptosis-inducing ligand sequentially activates prosurvival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 2003; 86: 126-35.
25. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di Pietro R. PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 2005; 202: 900-11.
26. Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003; 22: 3842-52.
27. Robertson NM, Zangrilli JG, Steplewski A, et al. Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival. J Immunol 2002; 169: 5986-96.
28. Morel J, Audo R, Hahne M, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005; 280: 15709-18.
29. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S. Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 1996; 271: 22961-4.
30. Gibellini D, Bassini A, Pierpaoli S, et al. Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 1998; 160: 3891-8.
31. Hunter I, Nixon GF. Spatial compartimentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells. Lipids rafts are essential for TNFalpha-mediated activation of RhoA but dispensable for the activation of the NF-kappaB and MAPK pathways. J Biol Chem 2006; 281: 34705-15.
32. Song JH, Tse MC, Bellail A, et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007; 67: 6946-55.
33. Venuraju SM, Yerramasu A, Corder R, et al. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55: 2049-2061.
34. Michowitz Y, Goldstein E, Roth A, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005; 45: 1018-24.
35. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41: 37S-42S.
36. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003; 23: 1398-404.
37. Nakajima H, Yanase N, Oshima K, et al. Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction. Jpn Heart J 2003; 44: 833-44.
38. Secchiero P, Gonelli A, Corallini F, et al. Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis 2010; 211: 333-6.
39. Secchiero P, Corallini F, Ceconi C, et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE 2009; 4: e4442.
40. Niessner A, Hohensinner PJ, Rychli K, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009; 30: 786-96.
41. Geroldi C, Ferrucci L, Bandinelli S, et al. Mild cognitive deterioration with subcortical features: prevalence, clinical characteristics, and association with acrdiovascular risk factors in communitydwelling older persons (The InCHIANTI Study). J Am Geriatr Soc 2003; 51: 1064-71.
42. Volpato S, Ferrucci L, Secchiero P, et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2011; 215: 452-8.
43. Lindner A, Charra B, Sherrand DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
44. Liabeuf S, Barreto DV, Barreto F, et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010; 25: 2596-602.
45. Secchiero P, Candido R, Corallini F, et al. Systemic tumor necrosis factor-realted apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006; 114: 1522-30.
46. Watt V, Chamberlain J, Steiner T, et al. TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2011; 215: 348-4.
47. Di Bartolo BA, Chan J, MR Bennett, et al. TNF-realted apoptosisinducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe-/-mice. Diabetologia 2011; 54: 3157-67.
48. Sedger LM, Glaccum MG, Schuh JC, et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002; 32: 2246-54.
49. Mi QS, Ly D, Lamhamedi-Cherradi SE, et al. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 2003; 52: 1967-75.
50. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, et al. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 2003; 52: 2274-8.
51. Zauli G, Toffoli B, di Iasio MG, et al. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010; 59: 1261-5.
52. Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012; 30(3): 1257-60.
53. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 2003; 83: 1069-112.
54. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 2724-31.
55. Kavurma MM, Tan NY, Bennett MR. Death receptors and their ligands in atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1694-702.
56. Kavurma MM, Bennett MR. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 2008; 75: 1441-50.
57. Sato K, Niessner A, Kopecky SL, et al. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006; 203: 239-50.
58. Niessner A, Sato K, Chaikof EL, et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114: 2482-9.
59. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003; 107: 2250-6.
60. Zauli G, Pandolfi A, Gonelli A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003; 92: 732-40.
61. Secchiero P, Corallini F, di Iasio MG, et al. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by downmodulating CCL8 and CXCL10 chemokine expression and release. Blood 2005; 105: 3413-9.
62. Kavurma MM, Schoppet M, Bobryshev YV, et al. Trail stimulates proliferation of vascular smooth muscle cells via activation of NFkappa B and induction of insulin-like growth factor-1 receptor. J Biol Chem 2008; 283: 7754-62.
63. Chan J, Prado-Lourenco L, Khachigian LM, et al. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 2010: 106: 1061-71.